State of Texas to Expand Newborn ScreeningJuly 28, 2006
PerkinElmer selected to supply tandem mass spectrometry systems and reagent kits to screen for multiple disorders.
BOSTON /BUSINESS WIRE/ -- PerkinElmer Inc., a global leader in health sciences and photonics markets, announced that it has signed a multi-year, multi-million dollar agreement to supply the state of Texas with instruments, software, and reagents to enhance the Texas newborn screening program. The technology will be used to test for metabolic disorders in the estimated 375,000 infants born in Texas each year.
Under the terms of the agreement, PerkinElmer will provide the Texas Department of State Health Services Laboratory with tandem mass spectrometry systems, as well as reagent kits and software enhancements to support the state's newborn screening program.
"We are pleased to work with the state of Texas on this important initiative, to provide its department of health with the technology to test for multiple disorders from a single sample," said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. "By utilizing this leading technology, we are able to detect potentially devastating metabolic disorders at an early stage to allow for better treatment and management options, leading to an improved quality of life."
With the addition of Texas, PerkinElmer has now signed long-term agreements for tandem mass spectrometry solutions with nine states, including Alabama, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania, and South Carolina.
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer Inc. is a global technology leader driving growth and innovation in health sciences and photonics markets to improve the quality of life. The company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available on the company's Web site or at 1-877-PKI-NYSE.
Most Read Articles